preclinical research and development

Accuitis is a late pre-clinical stage pharmaceutical company with multiple compounds in development that were discovered at Emory University. Its lead compound AN-018 is a small molecule validated in preclinical research to restore mitochondrial SIRT3 expression and healthy cellular function in neurodegenerative, age-related, and metabolic diseases such as Alzheimer's, Parkinson's disease, and methamphetamine addiction. The privately-funded company focuses on creating a preventive therapeutic for neurodegenerative disease progression.

Read more

drug discovery